Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
August 7, 2025
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being with us on this call covering our business update and financial results for the second quarter of 2025. Here with me today are my colleagues: Lisa Delfini, who serves as Trevi's Chief Financial Officer; Dr. James Cassella, our Chief Development Officer; and Farrell Simon, our Chief Commercial Officer. Lisa and I will offer a few remarks regarding the business and our financial performance. The team is glad to take whatever questions you might have. For Trevi, the first half of 2024 marked a major inflection point. Two trials delivered encouraging results: CORAL, which examined chronic cough among individuals who have Idiopathic Pulmonary Fibrosis, or IPF, and RIVER, which looked at patients suffering from Refractory Chronic Cough, or RCC. On the strength of those findings, we managed to bring in about $115 million, which lifted our cash and investments as of the end of June to roughly $204 million. With that, we have a sturdy runway for going after several important clinical milestones throughout all of our programs. This marks a thrilling moment in our story, and we believe our position is strong for executing our strategy and creating value. I want to bring everyone up to speed briefly on what we've been doing over the summer. You all know that at the start of June, we shared the topline results from the CORAL trial, where Haduvio hit the primary endpoint by producing a statistically significant reduction in 24-hour cough frequency at each dose level we examined. Once those topline figures were released, the complete dataset from the study arrived, and we're able to confirm that the secondary endpoint results matched what the topline findings showed. In particular, the quality of life measure for our patients, using the Leicester Cough Questionnaire, or LCQ, showed clear improvement, with a statistically significant decrease at the 54 mg and 108 mg BID doses. The LCQ is a 21-point scale that covers physical, social, and psychological domains. An improvement of 1.3 points in the total score is considered clinically meaningful. At 54 mg and 108 mg BID, the increases were 3.7 and 3.4 points, respectively, and both were statistically significant. For the total LCQ score at week six, P equals 0.01. For a six-week study, these results are strong. The LCQ is important for IPF patients; in fact, a publication from the large U.S. Pulmonary Fibrosis Foundation Registry demonstrated that poorer quality of life, as measured by the LCQ, was associated with a greater risk of worse health outcomes, including respiratory hospitalizations and mortality. At Trevi, keeping patients at the center of everything guides how we approach development and commercialization. During a patient advisory board meeting held not long ago, we went over the CORAL results so we could hear how patients responded to them. For patients considering a future treatment for cough, the two things that mattered most were reductions in how often and how severely they coughed, along with improvements in quality of life — which lines up with what physicians have also told us. Several patients shared that a change in cough like the one observed in CORAL would make an enormous, positive difference in their day-to-day lives. The thing that hit me hardest was how much coughing controls patients' daily lives—how they pull back or devise ways around it so they don't feel shame when coughing around other people. Now that we have those data, Jim and his team have been incredibly busy preparing for the FDA meeting at the close of Phase II and the studies that follow; as each trial gets underway, we'll offer more specifics, but let me give you a brief status report on what's at the front of the line over the next several months. First off, two major Phase I trials are currently in progress. We are wrapping up the TITL trial, which looks at how Haduvio affects breathing and whether it is safe in people with IPF. At the same time, we have a drug-drug interaction study underway that is checking what PK effects nalbuphine may have when it is taken together with pirfenidone and nintedanib — two antifibrotics that patients with IPF and other progressive fibrotic diseases use. Results from each of these trials ought to be ready before our end-of-Phase II meeting with the FDA. As for that end-of-Phase II meeting, we intend to ask for it sometime in Q4 of this year. Our key discussion points with the FDA involve getting on the same page regarding the Phase III trial plan for cough and IPF, along with any remaining NDA-supporting tasks, and in parallel the team has been preparing to kick off that Phase III effort in the first half of next year. Beyond IPF, we're preparing to look into other interstitial lung diseases too. This population would be made up of patients who don't have IPF but do have both lung fibrosis and cough. Our estimate is about 228,000 patients in that group, and somewhere between 50% and 60% of them deal with cough that isn't controlled. Compared with IPF cough, that's over twice the market opportunity, and the pulmonologists handling IPF cases are largely the same ones caring for these patients. Because of that, our clinical and commercial efforts stay efficient and we get synergies. Our plan is to request an FDA meeting sometime this year so we can discuss the non-IPF ILD study design and the protocol for that indication. Once we have the FDA's feedback, we'll be set to start the study. Last, we've been working on the next trial in refractory chronic cough; our expectation is that it will be a Phase II-B parallel arm study design examining dose ranging, and we plan to launch that trial during the first half of next year too. There's a great deal of clinical development planning happening at Trevi, along with preparatory work to align with the regulatory authorities. Ensuring we get this next set of trials right takes time; we'll share updates on next steps once we gain alignment and can see a clear path to study starts. Lisa will now walk everyone through the financials, and after that, we'll take whatever questions come up.
Lisa Delfini
executiveThanks, Jennifer, and hello everybody this afternoon. You can find the complete financial results for the quarter that wrapped up on June 30, 2025, in the press release we put out before this call, as well as in our Form 10-Q, which we submitted to the SEC today once trading had ended. During 2025's second quarter, our net loss came in at $12.3 million, versus a net loss of $12.4 million during the corresponding quarter of 2024. Research and development spending dropped to $9.4 million in 2025's second quarter, down from $10 million during the equivalent period in 2024. That decrease stemmed mainly from lower costs tied to the Phase II-A RIVER trial, our human abuse potential study, and the Phase II-B CORAL trial — each of which had been actively enrolling a year earlier; higher costs from our recently launched Phase I drug-drug interaction study, along with personnel and related expenses, partly offset that decline. General and administrative costs rose to $4.3 million in 2025's second quarter, compared with $3.3 million in the same quarter of 2024, driven largely by more professional fees plus personnel and related expenses. The personnel and related expenses were mostly attributable to added headcount. Roughly $500,000 out of the $1 million rise in total general and administrative expenses came from costs to prepare for SOX Section 404(b) concerning our internal controls. These obligations grow stricter as the company's market cap increases. As our readiness efforts continue, we anticipate roughly this expense level across the second half of 2025, and it may climb further down the road. On June 30, 2025, our cash and investments came to about $204 million. As Jennifer noted, the growth in our cash and investments largely resulted from the successful public offering we closed in June 2025 following the release of Phase II-B CORAL trial data, which generated gross proceeds of roughly $115 million, including the full exercise of the green shoe. With this cash and investment balance, we have runway into 2029, and it allows us to fund two Phase III trials of Haduvio for treating chronic cough in patients with IPF, our planned trial for chronic cough in patients with non-IPF ILD, our next trial in patients with RCC, the Phase I work Jennifer described, and it also supports pre-commercial planning activities; all told, Trevi is financially well positioned to carry out our business plan. That wraps up our prepared remarks. I'll hand the call back to the operator now for Q&A.
Faisal Khurshid
analystHi there, good afternoon, everyone. Thanks for fielding this; it sort of feels like things have settled down now. My question is about the respiratory depression trial. Could you give a bit of detail regarding how that trial is going and what the logistics involve? What I'm really asking is whether investors ought to view it as carrying some level of risk, or how we should think about what comes out of it. Thanks.
James Cassella
executiveHello, Faisal, this is Jim. Appreciate the question. As you're aware, the study we're running on respiratory safety examines the possible impacts of nalbuphine — of Haduvio — on breathing, measuring rate, CO2, and O2 among IPF patients. It's an assessment trial. Its purpose is characterizing whether any effects show up within this group of patients. I'd describe it as an informative trial; the FDA has wanted this kind of study to grasp the characteristics in those populations. On progress: the trial is underway; 2 sites are active; when I got to the company, we made some adjustments. We revised the protocol so it would be simpler, easier, and somewhat more straightforward. A modest delay arose from those changes. We remain on track, and we still expect to have data in time for the end-of-Phase II meeting.
Faisal Khurshid
analystUnderstood, thank you. Regarding the DDI study, could you explain why that's necessary given that you had prior antifibrotic use in your earlier IPF trials?
James Cassella
executiveYes, that's an excellent question. I believe it truly, you know, this is among those Phase I trials that simply must be characterized. This concerns more the metabolic, the possibility for metabolic PK drug interactions. Our drug gets metabolized mainly via CYP liver enzymes. Antifibrotics are going to be given to patients, pirfenidone and nintedanib. It's essentially a check-the-box exercise tied to the metabolic fate or how the drugs are broken down; for pirfenidone and nintedanib, no drug-drug interaction is anticipated. The rationale for conducting these trials, particularly prior to reaching Phase III, is that you wish to determine whether, when these medications are combined, any alteration occurs in the pharmacokinetics of our drug or the other drugs that might affect the compounds' overall efficacy. We are aware there's been some data out there where people discovered during Phase III that a pharmacokinetic interaction existed that directly impacted efficacy for one of the doses; this is a trial that was already on the books since IPF patients will be taking these drugs and it's basically an activity the FDA was anticipating. It was planned for us.
Faisal Khurshid
analystThanks, and appreciate you fielding our questions.
Jason Doerr
analystHello, this is Jason, filling in for Leland Gershell. We have a couple of items to ask about. The first one would be: what's your thinking on the main points that need to be resolved at the upcoming FDA meeting, as your team gets ready for the Phase III study of Haduvio in IPF cough? And on another one of your indications, what details can you share about the trial in non-IPF ILD chronic cough that will begin soon? Thanks.
Jennifer Good
executiveJim, it's your turn. Please proceed.
James Cassella
executiveGlad to cover either of those topics. When it comes to the Phase II meeting, that one matters a great deal. At the same time, for anyone moving into advanced clinical development, it's a pretty standard step. What we'll mainly present to the FDA at the end-of-Phase II meeting is the information gathered so far, particularly from CORAL, our definitive dose ranging study. The focus is on whether our program stands on solid ground, how we settle on the doses we intend to use, and above all on discussing the Phase III program—our readiness to enter Phase III and the details of the protocol. Usually, the Phase III protocol gets submitted along with the briefing document. We will certainly spend a lot of time discussing Phase III and securing their buy-in on it, and also, with an eye toward the NDA, the additional trials that either we or the FDA might determine are necessary so the package is sufficient for registration purposes. Items such as the DDI studies we're currently running will form part of that package. We'll also have that discussion with the FDA at that point. Another important takeaway from the end-of-Phase II meeting is the expected size of the safety database, how long a period the data in that safety database must cover, and—as we've anticipated from the start and have been saying—some form of long-term extension trial following our Phase III that will meet the FDA's requirements for longer-term exposure beyond what's needed to demonstrate preliminary safety and efficacy; that addresses that portion of the question. I'll stop there in case you have anything else to ask about it.
Jason Doerr
analystJason, that's excellent to hear. Thanks.
James Cassella
executiveRegarding non-IPF ILD, we've had many productive conversations with pulmonologists and KOLs working in this area. IPF, as you're aware, is an interstitial lung disease with a very clearly defined patient population. We've mentioned previously that numerous other patient groups also have interstitial lung disease, though not IPF — for instance, individuals with rheumatoid arthritis, Sjogren's, or systemic sclerosis. Our focus will be on that separate population, characterized by a specific degree of lung fibrosis along with a minimum level of cough; that's the segment we intend to examine closely. Since it exists on a continuum with the IPF population given the underlying lung fibrosis, we anticipate the endpoints and all other aspects will match those in IPF. Drawing on what the experts here have told us, I believe we have a solid grasp of what's required to carry out that study. Essentially, it's about broadening the patient base.
Jennifer Good
executiveJim, one thing I want to mention here: earlier I described the upcoming trial as a crossover design, something like a Phase II. But after reviewing everything from the IPF dataset and talking it over with the KOLs — the drug clearly helps with cough, so that entire proof-of-concept question, whether it actually does anything here, no one felt it was bringing much to the table anymore. So our approach has shifted toward running a study that is unquestionably a parallel-arm design, and that might help push this program forward more quickly. We'd like to get the agency aligned around that approach and figure out how to press ahead on it, and in some way have it converge with the IPF program at some point down the line. So I'd characterize it as a modest shift in how we're thinking, now that we have all the data in hand.
Jason Doerr
analystThat’s genuinely useful. Thanks once more.
Jennifer Good
executiveYes, thanks.
Annabel Samimy
analystHello, and thank you for letting me ask. I'd like to build on what was just mentioned about the parallel design used in the non-IPF ILD trial. I kept recalling that certain KOLs have said individuals with ILD—or, more accurately, those without IPF—experience disease progression that is largely comparable, and their cough shares a fibrotic mechanism or an interstitial lung disease mechanism too. Regarding a parallel design, could it perhaps even resemble a basket trial in some way? And if you stay with a Phase II rather than needing to swiftly advance into, or enter, a Phase III for a label expansion, would it simply be about demonstrating a certain degree of evidence that it works, since this mechanism appears so broad that it applies to every cough indication? That, I suppose, is my first rather tangled question.
Jennifer Good
executiveThe question of the day. That's what we've been arguing about in here. Jim, please go ahead.
James Cassella
executiveAnnabel? Yeah, the response is affirmative. Yeah, I'd describe it not so much as a basket trial, but rather as one where there's going to be a minimum threshold for entry that will let those patients who might have quite different types of comorbidities get into the study. What you're getting at is that there's a shared element here regarding the fibrosis and, in certain cases, even the progression. It'll perhaps be somewhat more expanded and less particular about specific kinds of comorbid conditions at entry. That's regarding the basic pool. I believe our thinking has become wider in that respect, thanks to the experts who believe the fibrosis is truly the essential criterion here.
Jennifer Good
executiveThen there's the cough.
James Cassella
executiveRight, the cough too. Clearly, the cough matters. With a parallel-group, or parallel-arm, design for the study, just consider what CORAL taught us. Jen pointed out that moving straight to a design like that makes a lot of sense at this stage — running a proof-of-concept trial really isn't necessary anymore. My sense is that all of us share that confidence. What matters most is that we'll be in a position to examine this initial Phase II-style study, take in what it shows, and, where it makes sense — along with additional talks with the FDA — potentially fold it into our IPF program as we advance these efforts side by side going forward. The crucial thing to keep in mind is that these efforts will proceed in parallel, and whenever an opening arises together with the appropriate kinds of data sets, we'll be able to hold those conversations about folding them together.
Annabel Samimy
analystAll right, understood, understood. All right. Regarding IPF, I suppose I remain quite impressed by the tolerability and the low rates of discontinuation you've shown, and I suppose if you pair that with the strong quality of life scores you achieved, my question at this point is, now that you've examined this data and you've truly had the opportunity to characterize some of these adverse events and how they occurred mostly upon initiation, irrespective of dose, is there anything further you can tell us about this? Do you genuinely believe you actually need to make any adjustments here? It appears as though everything aligned quite well for you on the tolerability front and on the quality of life front. It fits together nicely. Perhaps you could just offer a comment on that.
James Cassella
executiveYeah, I mean, we were extremely pleased with the CORAL data, with the result of that, the consistency of the findings on the primary and the key secondary and the other secondary endpoints. I believe we gained a great deal of knowledge. There aren't any actual adjustments that we're contemplating moving forward. Clearly, we'll be talking over the specifics of the Phase III design, which includes the dose selection, with the FDA at the end-of-Phase II meeting. I think we learned so much from the CORAL study. We're in a really strong position for how we intend to proceed.
Annabel Samimy
analystOkay, great. Thank you.
Jennifer Good
executiveThanks, Annabelle.
Alexa Deemer
analystHello, I'm Alexa Deamer, filling in for Josh Shimmer. Nice work on such a strong quarter. Here's what I'd like to know: now that we have additional, more comprehensive information for CORAL, what's your thinking regarding the dose or doses you plan to advance into the Phase III trial?
James Cassella
executiveThat's a good question. Looking across all of our data sets, it's clear to us that 54 mg BID truly stands out as the optimal dose. Its performance was excellent, and it delivered wide-ranging effects on both our primary and secondary endpoints. As we consider the path ahead, we recognize that 54 mg BID will be the essential dose we move forward with. Naturally, a placebo control will be included. We'll be talking through our rationale for dose selection with the FDA. I'm not able to get into all the details of those discussions, but I believe you can expect that 54 mg will be a critical dose that we advance.
Alexa Deemer
analystAll right, that's great. Thanks a lot.
Serge Belanger
analystHello, and good afternoon. You mentioned, I think, the complete findings from the CORAL trial that came in, I suppose, during the past month. Could you give us a bit more background on the LCQ data and explain how that ties into the primary endpoint? Will additional secondary endpoints be presented at medical conferences or in upcoming publications?
James Cassella
executiveCertainly. The Leicester Cough Questionnaire is an extremely commonly used tool for measuring quality of life. We've said before that our total assessment showed highly significant results. Looking at the domain scores — physical, psychological, and social — particularly, as I noted, at the 54 mg dose, we observe very, very pronounced effects across those domains. These examine how cough affects their physical domain, the social side of their life, and the psychological side of their life; we find clearly significant results, once again with attention on the 54 mg dose. The findings there are very, very clear. I think that genuinely assists; it supports the objective cough data we have. Objective cough is objective cough. An instrument measures it; here instead the patient is, you know, giving their view on how their life has shifted, their quality of life across these particular domains, and that rolls up into this total score. I think it supports things and brings the patient perspective into the picture alongside the decrease in cough frequency. The rationale for emphasizing that is that it's a very typical kind of assessment tool and, I'd say, a very important one when considering quality of life; we have examined the other, you know, patient reported outcome measures that we'll discuss at upcoming meetings. You know, patient global impressions, clinician global impressions; we spoke about the cough severity scores. There will be plenty of secondary endpoint, you know, patient reported outcome data arriving at later meetings.
Farrell Simon
executiveSerge, it's Farrell here.
Serge Belanger
analystSure, go ahead, Farrell.
Farrell Simon
executiveSerge, I simply wanted to piggyback on Jim's remarks. When it comes to reimbursement and value, the LCQ matters a great deal — it helps paint the full picture alongside the primary endpoint and the key secondary endpoints. Jennifer mentioned at the start that there's also a linkage here. If you look at the U.S. Pulmonary Fibrosis Foundation Registry, baseline LCQ showed a strong connection and correlation with impact on health outcomes. That will become apparent across a far longer stretch of time, and I believe that's something we'll examine as we move into a pivotal program. How does this affect things such as respiratory hospitalization and mortality?
Serge Belanger
analystThanks. Maybe a non-Jim question for Lisa.
James Cassella
executivePlease.
Serge Belanger
analystFor the rest of the year, until some of those bigger trials begin in 2026, should we be expecting OpEx to stay pretty much flat from these levels?
Lisa Delfini
executiveYeah, Serge, that's correct.
Serge Belanger
analystAll right, perfect. Thanks.
Jennifer Good
executiveThanks, Serge.
Deb Chatterjee
analystHello, and thank you for allowing me to ask. I've got a single inquiry regarding RCC. From what GST's most recent guidance indicates, it appears Kan II may now report out in the latter portion of 2026, with Kan I data arriving alongside it as one package. So I was wondering, do you know of any delays tied specifically to enrollment criteria? What's really the obstacle for this trial, and does that carry any consequences for the RCC study that you have in the works? I have a brief follow-up as well.
Farrell Simon
executiveDeb, it's Farrell here. I can only address what information we have. Look, we typically don't make statements when it's for competitive reasons. We lack any visibility into what's behind some of those holdups. What we do know is that, examining our opportunity in RCC, we could potentially be best in class for that indication. I believe that reflects the distinct approach we're pursuing by targeting a treatment resistant population — patients who haven't responded to other therapies. A substantial patient opportunity remains in that space.
Jennifer Good
executiveRight. I’d only say that ideally we’d have liked to review their data prior to launching our trial, but we aren’t going to pause and wait around for it. Given where things stand now, since their data seems to be moving later, we expect to be prepared to move ahead earlier than that. This won’t affect our.
James Cassella
executiveZero effect whatsoever. The robustness of the results from the RIVER trial, in my view, is going to help us considerably when it comes to conducting the following study. That is something, I believe, which draws attention not just from doctors but from patients too. I foresee no issue. What those delays stem from, I can't say. A large worldwide study is what they're conducting, as I understand it, yet the study we do next will be dose ranging, building on very dependable findings, and that will carry us quite far.
Deb Chatterjee
analystThanks. That was quite useful, and I have a quick question that follows up. It has to do with IPF. You brought up the drug-drug interactions involving nintedanib and pirfenidone. Are there any plans to look at interactions of a drug-like nature with nerandomylase?
James Cassella
executiveNo. Additional drug-drug interaction studies will be conducted, and those once more pertain to how metabolism works. Such studies are extremely routine. They have sat on our list of tasks to complete ahead of the NDA. No, I believe those two antifibrotics are the ones we will concentrate on.
Deb Chatterjee
analystThank you so much.
Jennifer Good
executiveThank you.
Ryan Deschner
analystThank you so much. Has anything else notable emerged in terms of trends, or any post hoc analyses from CORAL? Has the RIVER trial shifted how you think about dosing in either indication? Could you also share any further specifics regarding what you intend. To present at ERS afterward this year? Thanks.
James Cassella
executiveWe've taken a very thorough look at our dose effects through analysis. I believe we've definitely reached the conclusion that for us, 54 mg is a very key dose. Until we have that discussion with the FDA, I don't want to get ahead of our skis regarding how we might approach another dose in the trial. Based on all the analyses we've done internally, along with discussions with some experts and statisticians, I think it's really clear that for us, 54 mg is going to be an anchored dose.
Jennifer Good
executiveRight, Jim — beyond that, I’d simply say there’s nothing unexpected here, correct? The adverse events showed up soon after dosing and usually clear up fast. That matches the profile we’ve observed across essentially all kinds of trials.
James Cassella
executive27 mg will be used at a minimum as a titration.
Jennifer Good
executiveYeah, I'd say it's just solid. Regarding what you asked, Ryan, about presenting at ERS, we've had 2 abstracts accepted on RCC. Our IPF data is going to be submitted at CHEST, since we wanted that one shown in the U.S., which takes place in October in Chicago. Those are the 2 medical meetings where our data will hopefully be presented. We know we've gotten accepted at ERS for RCC, but we don't yet know about CHEST.
Ryan Deschner
analystExcellent. Congrats on the progress.
Jennifer Good
executiveThank you.
Brandon Folkes
analystHello, and thank you for fielding my question. I'd like to revisit something we've discussed before. I recognize that scheduling doesn't carry much of a commercial effect for the IPF patient group. Has any commercial analysis been performed, or do you have any perspective regarding how scheduling matters for the non-IPF ILD indications, specifically when it comes to prescribing behavior?
Farrell Simon
executiveThank you, Brandon. Farrell here. Some qualitative research has been conducted by us in that area, speaking with providers. If you consider the primary prescriber for that space, the pulmonologist remains that person; the pulmonologist truly is the point of contact, and we aren't seeing any sensitivity toward the mechanism underlying prescribing. We are returning to test a TPP that has been updated, drawing on the CORAL results. That will be tested across a wide variety of potential patient types; likewise, we don't expect any effect in non-IPF ILD.
Brandon Folkes
analystThanks, that's helpful. I guess I just have a single follow-up to better grasp what this respiratory depression study involves. Should anything unexpected crop up on the negative side, is there a requirement for us to report that to the DEA? When it comes to scheduling, is there a precedent we should be watching, like the outlier event, if something does turn up in that data related to scheduling, or has that matter been fully settled?
James Cassella
executiveIn my view, the respiratory safety study won't directly affect scheduling as such. What it's really about is simply establishing and demonstrating the characteristics we're examining in that study. My sense is that scheduling will ultimately hinge on abuse, liability, and potential on that front.
Brandon Folkes
analystExcellent, I appreciate you answering my questions.
Jennifer Good
executiveOf course, Brandon, thank you.
Kaveri Pohlman
analystHello, and thanks for the update and for fielding my question. Now that you're launching these Phase III trials, which involve a longer follow-up period than the Phase II had, what's your strategy for handling the placebo effect? And which difficulties did you resolve during the Phase II that leave you feeling confident about what's ahead? On top of that, looking at prior data and what you've experienced yourselves, do you expect any fresh obstacles in the Phase III? I suppose that one leans more toward a remedial question. One more thing I'd like to ask: since you're getting close to Phase III, could you explain whether any additional manufacturing steps would be needed for possible commercialization, and share any new thinking around partnering for commercialization? Thank you.
James Cassella
executiveI can handle the first six parts.
Jennifer Good
executiveThe entire development effort is yours to handle.
James Cassella
executiveI appreciate you asking that.
Jennifer Good
executiveThe way we limit you to one.
Kaveri Pohlman
analystWithin that, you'll find 5.
James Cassella
executiveMy sense is it reached double. That's right.
Kaveri Pohlman
analystThat's really thrilling.
James Cassella
executiveDon't worry about it. Regarding the Phase III, I believe we've gained an enormous amount of knowledge from this program up to now. In my view, CORAL served as an actual testing ground — a proving ground — for us when it came to the parallel group design; we took a great deal away from that study, and among the lessons learned was the rapid onset of effect, truly; we observed the drug effect, with efficacy showing up by that two week time point. From then on, things largely leveled off. My sense is we don't expect anything to shift past that. Across that entire six week study, we observed efficacy leveling off between weeks two to four. I believe that was acceptable; nothing new truly emerged later during the dosing weeks on the safety side. I don't believe we should expect the placebo effect — actually, I'm not certain we truly have a placebo effect. In my view, we had a properly controlled trial. Clearly, larger trials are always something we must keep an eye on; our effect size was very large. I don't believe we expect any problems there when it comes to managing that placebo effect. Given the kind of delta we currently have, I don't believe we'll encounter any fresh obstacles as we move ahead into longer term dosing trials. My view is we've genuinely put that to the test here; with the history of opiates, we don't observe anything that truly emerges later. Typically, things emerge sooner. I believe we observed that in our trial. I believe we observed that throughout the titration phase, where we did see adverse events that largely faded away during that titration phase and truly did not return while we kept our dose steady at the, even at the 108 level. I don't believe any surprises lie ahead for us. My view is we're truly in good shape there. Just a brief answer regarding your manufacturing question. We understand how to produce the drug, we understand how to provide the drug for larger trials. We've operated in Europe and we've operated in other locations. We understand how to get the drug distributed. No problems there on the Phase III side. This is — we have a seasoned team here that has conducted large trials previously, and we've already traveled to many locations. I don't expect any difficulties with that; that's everything I can recall.
Jennifer Good
executiveThat was really strong. I'll step in from here. Let me handle the partnering topic — it's an area Farrell and I consistently devote attention to. Clearly, the place where partnering matters most to us is likely Europe or Japan. When it comes to the U.S., Farrell is essentially moving full speed on figuring out how commercialization happens there. My view is that anyone who wanted those rights within the U.S. would need to acquire the company. Honestly, nothing changes on our end. At this point, we'd probably pursue a partner in Europe or Japan. Japan, perhaps, I'd say — though not Europe; our attention is squarely on the Phase III program, on how we reach the finish, generate solid data, and, of course, we're having the appropriate discussions with strategics when that's sensible for the company.
Kaveri Pohlman
analystThanks for that detail. I appreciate it, and nice work on the results.
Jennifer Good
executiveI appreciate that. Thanks for being so enthusiastic.
Mayank Mamtani
analystGood afternoon, everyone, and thanks for making room for us. Would you mind discussing which dose levels are being tested across the 2 Phase I studies? We're also wondering whether the dose-finding effort involving IPF chronic cough and RCC provides any assistance on the IP strategy front. Then, as a quick follow-up regarding the CHEST presentation on the IPF data: might there be any FVC data available? Perhaps it is broken out according to background therapy or without background therapy. Appreciate you fielding this.
Jennifer Good
executiveJim, I'll handle the CHEST item. You can take that one. The remaining questions, I believe, are mine.
James Cassella
executiveThat's fine.
Jennifer Good
executiveFor CHEST, the bulk of what we'll share is essentially the primary data that has already been made public in IPF. Publishing isn't something we intend to do. Like we've consistently said, this is a safety measure — though that isn't quite right either. The trial ran too briefly to truly capture anything meaningful on that front. I don't want anyone getting their hopes up that we have something novel to release. It will center on our primary data. On the IP matter, Jim, I can address that too. In every trial we conduct, this is something we're constantly watching for. Once a study wraps up, we sit down with our IP attorneys, go through all the data, and search for anything that could make its way into the label and support claims — whether around dosing or otherwise. That work happens continuously here. I believe we'll need to be patient, examine the data, and if anything unexpected or non-obvious turns up, we'll pursue dosing claims based on it. That remains an ongoing effort.
James Cassella
executiveWhen we look at the Phase I trials, those are single dose strength studies that we compare. In the title study, it's a dose escalation that goes up to the top dose being used in that trial. As for the EI study, it's against pirfenidone and nintedanib, testing various dosing regimens against a single dose strength of nalbuphine.
Mayank Mamtani
analystThank you.
Jennifer Good
executiveThank you, Mayank.
Jennifer Good
executiveThanks for being with us on today's call. Make the most of what's left of summer. Once the call wraps up, we're around for any follow-ups you might have. Simply send an email to Lisa or to me, and we'll find a slot for you. Thanks so much.
Operator
operatorThe conference call has now concluded. Thank you for attending today's presentation.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.